AIMS: Immune checkpoint inhibitors have become a successful treatment in metastatic melanoma. The high response rates in a subset of patients suggest that a sensitive companion diagnostic test is required. The predictive value of programmed death ligand 1 (PD-L1) staining in melanoma has been questioned due to inconsistent correlation with clinical outcome. Whether this is due to predictive irrelevance of PD-L1 expression or inaccurate assessment techniques remains unclear. The aim of this study was to develop a standardised digital protocol for the assessment of PD-L1 staining in melanoma and to compare the output data and reproducibility to conventional assessment by expert pathologists. METHODS AND RESULTS: In two cohorts with a total o...
2. Abstract Degree Project, Programme in Medicine Immunologic phenotyping and S100 as biomarkers for...
The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, th...
This study evaluated the expression of PD-L1 in immunotherapy-naïve metastatic melanoma patients to ...
AIMS: Immune checkpoint inhibitors have become a successful treatment in metastatic melanoma. The hi...
Background PD-1-based immune checkpoint inhibition (ICI) is the major backbone of current melanoma ...
Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not a...
Objective: Prognosis of patients with metastatic melanoma has dramatically improved over recent year...
INTRODUCTION: PD-L1 is established as a predictive marker for therapy of non-small cell lung cancer ...
Abstract Background Immune checkpoint inhibitors (ICIs) have changed the clinical management of mela...
Background: Checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, yielding...
International audienceBackground: Immune checkpoint therapies (ICTs) targeting the programmed cell d...
Abstract Programmed cell death ligend-1 (PD-L1) expression by immunohistochemistry (IHC) assays is a...
Purpose: Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for respon...
Targeting of the programmed cell death protein (PD-1)/programmed death-ligand 1 (PD-L1) axis with ch...
The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, th...
2. Abstract Degree Project, Programme in Medicine Immunologic phenotyping and S100 as biomarkers for...
The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, th...
This study evaluated the expression of PD-L1 in immunotherapy-naïve metastatic melanoma patients to ...
AIMS: Immune checkpoint inhibitors have become a successful treatment in metastatic melanoma. The hi...
Background PD-1-based immune checkpoint inhibition (ICI) is the major backbone of current melanoma ...
Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not a...
Objective: Prognosis of patients with metastatic melanoma has dramatically improved over recent year...
INTRODUCTION: PD-L1 is established as a predictive marker for therapy of non-small cell lung cancer ...
Abstract Background Immune checkpoint inhibitors (ICIs) have changed the clinical management of mela...
Background: Checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, yielding...
International audienceBackground: Immune checkpoint therapies (ICTs) targeting the programmed cell d...
Abstract Programmed cell death ligend-1 (PD-L1) expression by immunohistochemistry (IHC) assays is a...
Purpose: Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for respon...
Targeting of the programmed cell death protein (PD-1)/programmed death-ligand 1 (PD-L1) axis with ch...
The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, th...
2. Abstract Degree Project, Programme in Medicine Immunologic phenotyping and S100 as biomarkers for...
The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, th...
This study evaluated the expression of PD-L1 in immunotherapy-naïve metastatic melanoma patients to ...